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Monogenic primary immunodeficiency syndromes can affect one or more endocrine 
organs by autoimmunity during childhood. Clinical manifestations include type 1 diabe-
tes mellitus, hypothyroidism, adrenal insufficiency, and vitiligo. Lipopolysaccharide (LPS)-
responsive beige-like anchor protein (LRBA) deficiency was described in 2012 as a novel 
primary immunodeficiency, predominantly causing immune dysregulation and early onset 
enteropathy. We describe the heterogeneous clinical course of LRBA deficiency in two 
siblings, mimicking an autoimmune polyendocrine disorder in one of them in presence of 
the same underlying genetic mutation. The third child of consanguineous Egyptian par-
ents (Patient 1) presented at 6 months of age with intractable enteropathy and failure to 
thrive. Later on, he developed symptoms of adrenal insufficiency, autoimmune hemolytic 
anemia, thrombocytopenia, and infectious complications due to immunosuppressive 
treatment. The severe enteropathy was non-responsive to the standard treatment
and led to death at the age of 22  years. His younger sister (Patient 2) presented at 
the age of 12 to the endocrinology department with decompensated hypothyroidism, 
perioral vitiligo, delayed pubertal development, and growth failure without enteropathy 
and immunodeficiency. Using whole exome sequencing, we identified a homozygous 
frameshift mutation (c.6862delT, p.Y2288MfsX29) in the LRBA gene in both siblings. To 
our knowledge, our patient (Patient 2) is the first case of LRBA deficiency described with 
 
Abbreviations: Ab, antibodies; aTPO, antithyroperoxidase; AP, alkaline phosphatase; BEACH, the beige and Chediak–Higashi 
syndrome-domain; GAD65, glutamat-decarboxylase; IGFBP3, insulin-like growth factor-binding protein 3; IA2, islet autoan-
tibody-2; IAA, insulin autoantibodies; IGF, insulin-like growth factor; LYST, lysosomal trafficking regulator; LPS, lipopoly-
saccharide; PHA, phytohemagglutinin; PTH, parathormone; SEE, staphylococcal enterotoxin E; TSH, thyroid-stimulating 
hormone; TG, thyroglobulin.
FigUre 1 | (a) Chest CT-scan of Patient 1 showing severe polyserositis with 
pleural and pericardial effusions; (B) patient 2 with progressive perioral vitiligo 
without other abnormalities in her face; and (c) ultrasound of the thyroid 
gland in Patient 2 showing a hypotrophic thyroid gland with 2.5 ml volume 
and several nodules <5 mm.
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predominant endocrine phenotype without immunodeficiency and enteropathy. LRBA 
deficiency should be considered as underlying disease in pediatric patients presenting 
with autoimmune endocrine symptoms. The same genetic mutation can manifest with 
a broad phenotypic spectrum without genotype–phenotype correlation. The awareness 
for disease symptoms among non-immunologists might be a key to early diagnosis. 
Further functional studies in LRBA deficiency are necessary to provide detailed informa-
tion on the origin of autoimmunity in order to develop reliable predictive biomarkers for 
affected patients.
Keywords: autoimmune thyroiditis, lipopolysaccharide responsive beige-like anchor gene, autoimmune 
enteropathy, stem cell transplantation, genotype–phenotype correlation
inTrODUcTiOn
A series of monogenic primary immunodeficiency disorders 
(PIDs) has been described, causing a combination of immuno-
deficiency and multi-endocrine disorders. A prime example is 
the autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy syndrome (APECED) as a monogenic immune dis-
order caused by mutations in autoimmune regulatory (AIRE) 
gene. Further examples include immunodeficiency, polyendo-
crinopathy, x-linked (IPEX) syndrome (1), Stat5b-deficiency (2), 
CD25-deficiency (3), and CTLA-4-haploinsufficiency (4), which 
all can present with immunodeficiency and endocrine disorders. 
Mutations in Lipopolysaccharide responsive beige-like anchor 
(LRBA) gene have been introduced as a PID with a predominant 
polyautoimmune phenotype (5, 6). Affected individuals typically 
present with severe enteropathy in early life and may suffer from 
hypogammaglobulinemia, pulmonary disease, lymphoprolifera-
tive disorder (7), and infancy-onset type 1 diabetes mellitus (8). 
Recently, Alkhairy et  al. described autoimmune thyroiditis as 
a part of the disease symptoms in 3 out of 31 affected patients 
(9). A  predominant endocrine phenotype of LRBA deficiency 
without symptoms of enteropathy and immunodeficiency has not 
been described yet. Here, we describe the detailed immunology 
and endocrine profile of two LRBA-deficient siblings sharing 
the same genetic mutation with lack of LRBA protein expres-
sion. The older sibling (Patient 1) suffered from a combination 
of complex immune dysregulation caused by LRBA deficiency, 
whereas the younger sibling (Patient 2) predominantly developed 
multi-endocrine symptoms with thyroiditis, vitiligo, and growth 
retardation.
PaTienTs anD MeThODs
Patient 1
The third of the four children of consanguineous Egyptian parents 
presented, at the age of 6 months, with intractable diarrhea result-
ing in maldigestion and malabsorption. Over the first 4  years 
of life, the patient required steroid medication. Consecutively, 
secondary adrenal insufficiency with hypocortisolemia occurred. 
There was no evidence of underlying growth hormone deficiency 
or autoimmunity against pituitary gland and testicular tissues. 
Endocrine features such as growth retardation, delayed puberty, 
and osteoporosis were related to the severe course of chronic 
illness. By the age of 14  years, two episodes of autoimmune 
hemolytic anemia and one episode of rhabdomyolysis occurred, 
followed by polyserositis (Figure 1A). Initial combinatorial treat-
ment with glucocorticoids and sirolimus resulted in short remis-
sion. However, further intensification of the immunosuppressive 
therapy including administration of azathioprine and tacrolimus 
as well as splenectomy were necessary to ameliorate autoimmun-
ity. The severe enteropathy continued to be the predominant 
complaint and remained non-responsive to immunosuppres-
sive treatment (Table 1). The functional short bowel syndrome 
resulted in severe cachexia with a body weight of 33.5  kg at 
20  years despite long-term parenteral nutrition. The course of 
the disease was complicated by secondary end organ damages. 
The patient suffered from liver disease, esophageal varicose veins, 
and neuropathy. The option of allogeneic hematopoietic stem cell 
transplantation (alloHSCT) combined with short bowel and liver 
transplantation was considered at that stage. Intensified immu-
nosuppression led to severe recurrent infections refractory to 
TaBle 1 | The course of the disease and clinical complications.
immunosuppression
Patient 1
6 months: severe pan-colitis, failure to thrive Steroids
2 years old: chronic diarrhea, TPN-dependent
5 years old: hearing loss
10 years old: subclavian vein thrombosis
14 years old: AI-hemolytic anemia, rhabdomyolysis Splenectomy
15 years old: severe cachexia, liver failure Ciclosporine
17 years old: recurrent GI-bleeding (ICU) Tacrolimus
20 years old: neuropathy, seizure Sirolimus
21 years old: 2× AI-hemolytic anemia, 
AI-thrombocytopenia, and polyserositis
Azathioprine
21 years old: chronic osteomyelitis (complete 
destruction of the joint)
22 years old: respiratory failure, death
Patient 2
12 years old: AI-thyreoiditis, starting on l-thyroxine None
14 years old: vitiligo None
15 years old: 2× decompensated hypothyroidism None
TaBle 2 | immunology and endocrinology work-up in two siblings with 
lrBa deficiency syndrome.
lab results normal range Patient 1 Patient 2
WBC 4–11/nl 9.0 6.5
Hb 11–15 g/l 11.2 10.7
Thrombocytes 200–400/nl 289 185
Lymphocytes (CD3+) 2–4.8/nl 3.7 2.3
Granulocytes 1.8–7.1/nl 4.7 3.9
CD4+ T-cells 700–1400/μl 505a 594
CD8+ T-cells 200–900/μl 314a 585
Naive CD4+(CD4+CD45RA+CD62L+) 220–873/μl n.a. 185
Naive CD8+(CD8+CD45RA+CD62L+) 100–470/μl n.a. 368
DNT (CD3+TCRab+CD4 −CD8 −) 0–5% n.a. 5%
Regulatory T-cells 
(CD4+CD25+CD127low)
4–12% n.a. 7.1%
Effector memory T4 
(CD4+CD45RO+CD62L−)
4–20% n.a. 9%
Central memory T4 
(CD4+CD45RO+CD62L+)
8–50% n.a. 48%
B-cells (CD19+) 100–500/μl 104a 164
Naive B-cells (CD19+CD27−IgD+) 150–515/μl n.a. 220
Switched memory B 
(CD19+CD27+IgD−)
5–77/μl n.a. 20
Non-switched memory B 
(CD19+CD27+IgD+)
2–77 n.a. 36
NK–cells (CD3−CD56+) 90–600/μl 95 90
IgG 590–1400 mg/dl 1159 1220
IgM 50–317 mg/dl 45 44
IgA 70–250 mg/dl <7 17
IgE <100 U/ml 1.2 1
Coombs test negative +++a −
Anti-thrombocyte-ab negative − +
Anti-granulocyte-ab negative ++a +
TSH 0.5–3.6 mU/l 1.7 200
fT4 0.9–1.6 ng/dl 1.4 0.1
PTH 15–65 pg/ml 24a >700
25-OH-vitD 20–30 ng/ml <5a <4
Calcium 2.1–2.55 mmol/l 2.1 2.44
IgfBP3 2.2–4.6 μg/ml 2.1a 2.5
HGH 0.14–14 ng/ml n.a. 1
IGF-1 190–805 ng/ml 466a 170
TG-ab <40 IU/ml n.a. >3000
aTPO-ab <35 IU/ml 76a 2818
Adrenal-ab negative − −
TRAK <1 U/l 0.03a 0.04
HbA1C 4.8–5.9% Hb 4.9 5.1
IFT ANA <1:10 1:160a 1:320
GAD-ab <50 mGAD/ml n.a. <50
Anti-IA2-Ab <8 U/ml <8a <8
Insulin-ab <0.4 IU/ml <0.4a <0.4
Anti-gliadin-ab <15 U/ml 12a 35
Anti-transglutaminase-ab <12 U/ml 10a 1
Bold, abnormal values; n.a., not available.
aValues were obtained at 14 years of age.
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antibiotic treatment and surgical intervention. The patient lost his 
lower leg due to chronic osteomyelitis at the age of 21 years prior 
to scheduled from a HLA-identical family donor. The patient died 
due to recurrent septic complications and respiratory failure after 
lower leg amputation prior to the transplantation.
His initial laboratory results showed mild CD4+-lymphopenia 
[CD4 505/μl (NR 700–1300)] with normal distribution of CD8+ 
T-cells, NK-cells (CD3−CD56+), and B-cells (CD19+). IgA defi-
ciency was observed with normal IgG, slightly reduced IgM, low 
tetanus vaccine antibodies, and normal hepatitis B vaccine anti-
bodies. Thyroid hormones, growth factors, and PTH were within 
the normal range with low levels of vitamin D [<5  ng/ml (NR 
20–30)] (Table 2). Sanger sequencing showed no FoxP3 mutation 
indicative of IPEX syndrome, and the presentation was evaluated 
as IPEX-like.
Patient 2
The younger sister of Patient 1 was admitted to the endocrinol-
ogy department at the age of 12  years with decompensated 
hypothyroidism [TSH > 200 mU/l (NR 0.5–3.6)]; fT4 0.1 ng/dl 
(NR 0.9–1.6), related growth retardation (<P3), pubertal arrest, 
and progressive perioral vitiligo (Figure 1B). Her past medical 
history was unremarkable with regard to relevant infections and 
gastrointestinal symptoms. We observed high thyroid antibody 
titers [aTPO-ab > 2818 IU/ml (NR < 35); TG-Ab > 3000 IU/ml 
(NR < 40)]. Low IGF-1 [170 ng/ml (NR 190–805)] and IGFBP3 
[2.5 μg/ml (NR 2.2–4.6 μg/ml)] were detected with normal level 
of cortisol in plasma. Serum-calcium and phosphate were at the 
lowest normal range. We observed low vitamin D [<4 ng/ml (NR 
20–45)], elevated AP [173 U/l (NR 47–119)], and elevated PTH 
[764 pg/ml (NR 15–65)]. These parameters normalized after oral 
calcium and vitamin D supplementation without evidence of 
malabsorption. Bone density – measured by peripheral quantita-
tive CT-scan – was within the lower normal range. Ultrasound 
evaluation revealed a small thyroid gland [2.5 ml (NR 5.7–13.3)] 
with multinodular (<5 mm) texture, transformed in accordance 
to ongoing thyroid autoimmunity (Figure 1C). Since there was no 
biochemical evidence of underlying growth hormone deficiency, 
the progressive growth retardation in this patient was related to 
long-term preexisting hypothyroidism. Following initiation of 
medical substitution, fT4 and TSH normalized subsequently.
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Echocardiography revealed a marked pericardial effusion 
resolving after thyroxin substitution. On further follow-up, bone 
age remained significantly retarded. Furthermore, slightly elevated 
anti-gliadin-IgG [35 U/ml (NR < 12)] was measured in presence 
of normal anti-transglutaminase antibodies. WBC showed mild 
thrombocytopenia with detectable anti-thrombocyte antibodies 
[185/nl (NR 200–400)] and slightly reduced hemoglobin [Hb 
10.1 g/dl (NR 11–15.5)].
The lymphocyte subset analysis showed mild CD4− lympho-
cytopenia [594/μl (NR 700–1400)] with normal naive population 
(CD4+CD45RA+CD62L+) and normal distribution of effec-
tor memory (CD4+CD45RO+CD62L−) and central memory 
(CD4+CD45RO+CD62L+) T-cells, normal B-cells (CD19+) with 
normal naive (CD19+CD27−IgD+), memory (CD19+CD27+), 
switched memory (CD19+CD27+IgD−), non-switched memory 
B-cells (CD19+CD27+IgD+), and normal NK-cells (CD3−CD56+). 
Tregs (CD4+CD25+CD127low) were within the normal range. 
As in her brother, IgA deficiency was detected [17  mg/dl (NR 
70–300)] with normal IgG and slightly reduced IgM levels in 
plasma (Table 2). After thyroid hormone substitution and vita-
min D supplementation, the patient re-started to grow and later 
experienced delayed menarche at the age of 16 years. The patient 
is currently 19 years old and on thyroid hormone substitution as 
well as oral vitamin D and calcium supplements. No immunosup-
pressive therapy has been initiated yet.
genetic analysis Using Whole  
exome sequencing
Genetic analysis was performed after informed consent by the 
parents. Genomic DNA from peripheral blood cells was isolated 
using the QIAamp® DNA Blood Mini Kit (Qiagen, Courtaboeuf, 
France) according to manufacturer’s instructions. Whole exome 
sequencing (WES) was performed on the genomic platform 
of Institut IMAGINE’s. Agilent SureSelect librairies were pre-
pared from 3 μg of genomic DNA sheared with a Covaris S2 
Ultrasonicator. Exons regions were captured using the Agilent 
Sure Select All Exon 51Mb V5 (AGILENT, Les Ulis, France) 
and sequenced using a HiSeq2500 next generation sequencer 
(Illumina) on the Genomic Platform of Institut IMAGINE, Paris. 
Depth of coverage obtained for each sample was around 100× 
with >98% of the exome covered at least 15-fold. Paired-end 
sequences were then mapped on the human genome reference 
(NCBI build37/hg19 version) using the Burrows-Wheeler 
Aligner. Downstream processing was carried out with the 
genome analysis toolkit (GATK), SAMtools, and Picard, each 
following documented best practices.1 Variant calls were made 
with the GATK Unified Genotyper. All variants were annotated 
using the in-house software (PolyWeb) developed by Paris 
Descartes University Bioinformatics platform. All the annota-
tion process was based on the 72 version of ENSEMBL database. 
Analysis of genome variations was made using the PolyWeb 
software. Variants were compared to the ones already present 
in US National Center for Biotechnology Information database 
(10) of SNP, 1000 Genome, and Exome Variant Server databases. 
1 http://www.broadinstitute.org/gatk/guide/topic?name=best-practices
The impact on the protein function was predicted using three 
algorithms: Polyphen 2,2 SIFT (Sorting Intolerant From Tolerant, 
J. Craig Venter Institute), and Mutation Taster.3 To confirm the 
mutation by Sanger sequencing, genomic DNA was amplified 
by standard techniques using oligonucleotide primers flank-
ing the exon 46 on the Ensembl transcrit ENST00000357115 
of LRBA (forward 5′-TTTCCCTCCCTATTGGCAGC-3′, 
lower 5′-ACAGCAAGCATCTGAAGGGG-3′) using TaqDNA 
Polymerase (Life Technologies, Saint-Aubin, France). After puri-
fication with the QIAquick PCR Purification kit (Qiagen), PCR 
fragments were sequenced using the same primers by Eurofins on 
the Genomic Platform of Université Paris Descartes.
cell culture and immunoblotting
PBMC were collected from blood using standard density gradi-
ent separation method. Cells were either cultivated right away 
or frozen and activated upon thawing. T-lymphocytes were 
activated by staphylococcal enterotoxin E (SEE 0.1  ng/ml) or 
Phytohemagglutinin (PHA 12.5 μg/ml) and cultured in Panserin, 
5% SAB, 1% penicillin/streptomycin, and 1% glutamine medium. 
At day 3 of culture and further on three times per week, IL-2 
(100 ng/ml) was added to maintain cell proliferation. Cell lysates 
were prepared according to standard methods, separated using 
3–8% Tris-acetate gels (Invitrogen), transferred onto PVDF 
membrane, and immunoblotted with primary antibodies to LRBA 
(HPA023597, Sigma), Ku70 (MA5-13110, Thermo scientific), 
and secondary antibodies to rabbit and mouse (Santa Cruz).
resUlTs
Using WES, we identified a total of 14 genes with homozygous 
variants in both siblings. These homozygous variants included 
two genes with missense variants predicted to be damaging 
and one frameshift in the LRBA gene. The segregation of the 
LRBA variant was checked and correlated to the disease symp-
toms, as shown in Figure 2. None of the healthy siblings were 
homozygous for the LRBA variant. Two other homozygous 
variants were also detected in both affected siblings. The first 
variant was located in the gene encoding Fibrinogen gamma 
chain (FGG rs775086103; c.620A  >  G; p.Tyr207Cys). This 
gene has been reported in context of blood clotting disorders 
including familial dysfibrinogenemia, hypofibrinogenemia, 
and thrombophilia. There is no evidence of immunodeficiency 
in described patients. The second homozygous variant in both 
siblings was found in the gene encoding for chorionic soma-
tomammotropin hormone 2 (CSH2 rs549767039; c.-62A > G). 
This variant was located inside the 5′UTR, which belongs to the 
non-coding exonic sequence. CSH2 is expressed mainly in the 
placenta and utilizes multiple transcription initiation sites. No 
association is known with immunodeficiency or autoimmunity 
(Table 3).
Lipopolysaccharide responsive beige-like anchor expression 
was analyzed by Western blot. Compared to a healthy control, we 
2 http://genetics.bwh.harvard.edu/pph2/ 
3 www.mutationtaster.org
FigUre 2 | sanger chromatograms of two affected patients, their clinically healthy siblings, and parents. The yellow bar is indicating a point mutation in 
LRBA. Both affected siblings found to share the same mutation, whereas their parents were heterozygous carriers. Family pedigree double lining, consanguinity; 
half-fill, heterozygous; solid black, homozygous.
TaBle 3 | list of homozygous variants detected by whole exome sequencing in both affected patients.
gene nucleotide amino acid chromosome gene function
FGG c.620A > G p.Tyr207Cys 4q32.1 Fibrinogen gamma chain. Related to familial hypo- and dysfibrinogenemia
CSH2 c.-62A > G Non-coding exonic 17q23.3 Chorionic somatomammotropin hormone 2, carbohydrate, and protein metabolism during 
pregnancy
lrBa c.6862delT p.Y228MfsX29 4q31.1 B-cell function, lysosomal trafficking, and autophagy
Bold characters highlight the importance of the finding.
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observed a complete absence of LRBA protein in both affected 
siblings. The pathogenicity of the homozygous variant found by 
WES was confirmed by the complete lack of the LRBA protein 
(Figure 3).
Diagnostic work-up of the clinically healthy family members 
revealed an interindividual variable degree of autoimmune 
thyroiditis. Both LRBA-heterozygous parents showed low TSH 
with normal fT3 and slightly increased fT4. Thyroid antibodies 
(TG-ab and aTPO-ab) were detected in both parents and het-
erozygous sister in keeping with the diagnosis of a compensated 
thyroid dysfunction. The autoimmune thyroiditis in heterozy-
gous family members is, in contrast to our Patient 2, associated 
with an asymptomatic clinical course of thyroid disease. Specific 
antibodies against adrenal tissue (21-hydroxylase) as well as 
antibodies typically associated with type 1 diabetes (GAD65, IA2, 
IAA) were proven negative in all family members. There was no 
history of gonadal insufficiency or impaired growth in parents 
or siblings. The immunology parameters were within the normal 
range for all of them.
DiscUssiOn
We observed a heterogeneous clinical manifestation of LRBA 
deficiency in two siblings of a consanguineous family with a 
frameshift mutation, resulting in truncation of the LRBA protein. 
Our patient (Patient 2) presented with predominant endocrine 
FigUre 3 | assessment of lrBa protein expression by Western blot. 
A complete lack of LRBA protein was observed in both affected siblings.
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symptoms of hypothyroidism, growth retardation, delayed 
menarche, vitiligo, and rickets but without type 1 diabetes mel-
litus and enteropathy or immunodeficiency.
Pediatric patients with primary immunodeficiensies may 
present with variable and combined multi-organ symptoms in 
early childhood. Heritable monogenic PID with a predominant 
autoimmune phenotype has overlapping symptoms with the 
clinical spectrum of endocrine disorders (10). Whereas some of 
the patients suffer from a classic combination of symptoms, others 
might initially and exclusively present with endocrine symptoms 
causing a delay in diagnosis and treatment. Early diagnosis of the 
underlying disease is important in order to provide optimal treat-
ment but may be a challenge in such patients. Within the spec-
trum of autoimmune endocrine diseases, LRBA deficiency has to 
be considered in addition to IPEX, CTLA-4-haploinsufficiency, 
CD25−, and Stat5b-deficiency.
Lipopolysaccharide responsive beige-like anchor is a member 
of the beige and Chediak–Higashi syndrome (BEACH)-domain 
containing protein family. It has a significant homology with 
LYST, another member of BEACH family (11). LRBA is involved 
in critical cellular interactions such as apoptosis and autophagy 
and plays a fundamental role in the regulation of immune 
system. However, the detailed pathomechanism underlying the 
variable symptom complex in LRBA deficiency is not completely 
understood yet.
Maintaining the balance between immunity and autoimmun-
ity requires a complex interaction of activating and inhibiting 
factors. Firstly described in 1987, the glycoprotein CTLA-4 
(12), mainly localized in intracellular vesicles of Tregs, is a key 
regulator molecule in this cascade (13). By acting as an early 
checkpoint, CTLA-4 has a major influence on maintaining 
self-tolerance (14, 15). There is evidence that LRBA controls 
CTLA-4 expression and thereby supports its transendocytotic 
function by preventing its degradation in recycling lysosomes 
(16). In support, Tregs of LRBA-deficient patients expressed 
lower intracellular and membrane levels of CTLA-4 without an 
alteration of the CTLA-4 mRNA. Two LRBA-deficient patients 
with detectable moderate residual LRBA protein were reported 
to have higher CTLA-4 levels suggesting a quantitative correla-
tion between CTLA-4 deficiency and residual LRBA protein in 
LRBA-deficient patients (16).
The recent description of the extended phenotype of the dis-
ease in 22 genetically confirmed cases of LRBA deficiency showed 
immune dysregulation (95%), organomegaly (86%), recurrent 
infections (71%), and hypogammaglobulinemia (57%) as the 
main clinical complications, whereas 81% of these LRBA-deficient 
patients had normal T-cell counts, and 73% had reduced Tregs 
numbers (6). Both patients reported by Schreiner et al. suffered 
from endocrine symptoms in addition to underyling enter-
opathy and immunodeficiency (8). Autoimmune thyroiditis was 
observed by Alkhairy et al. in 3 out of 31 patients with underlying 
LRBA deficiency syndrome (9). However, none of these patients 
presented with an autoimmune thyroiditis as the major clinical 
manifestation. GH deficiency per se has not been associated with 
LRBA deficiency. Indeed, most of the affected patients seem to 
develop secondary growth failure in addition to their gastrointes-
tinal dysregulation and malabsorption. This is a common feature 
of a series of other primary immunodeficies as well. However, 
Patient 2 did not suffer from gastrointestinal disease or malabsorp-
tion previously. There was no biochemical evidence of underlying 
growth hormone deficiency. The progressive growth retardation in 
this patient was related to long-term preexisting hypothyroidism. 
As observed in this cohort and in additional reports, the clinical 
course of the disease remains highly variable (6, 9).
The suggested selective regulation of CTLA-4 degradation 
by LRBA is tempting to compare immune defects of LRBA with 
CTLA-4-deficient patients. Schubert et  al. reported 19 patients 
with a genetically confirmed CTLA-4-haploisufficiency (4). 
Only 12 patients presented with severe clinical manifestations 
including enteropathy (78%), hypogammaglobulinemia (76%), 
granuloma (66%), autoimmune thrombocytopenia (35%), and 
autoimmune hemolytic anemia (28%). Autoimmune thyroiditis 
was present in two patients as a part of a polyautoimmune disor-
der. Isolated autoimmune endocrine disorder was not reported in 
this cohort (4). Recently, Slatter et al. reported the outcome in a 
group of CTLA-4 deficient patients (n = 8) undergoing alloHSCT. 
Autoimmune endocrine disorders (type 1 diabetes, exocrine pan-
creas insufficiency and thyroiditis) were reported in two patients 
as one part of their complex autoimmune disorder. Interestingly, 
signs of isolated endocrine autoimmunity were observed among 
family members of these two patients suggesting a minor disease 
activity in these individuals without being diagnosed as CTLA-4-
deficient previously (17).
As mentioned above, the majority of LRBA- and CTLA-
4-deficient patients show a relevant Treg dysfunction with 
immune dysregulation as their main clinical symptom resulting 
in an IPEX-like disorder. However, a series of proven CTLA-4-
deficient individuals are asymptomatic despite disturbed Treg 
cell suppressive ability (4). As observed in our Patient 2, LRBA 
deficiency can also present with normal T- and B-cell subpopula-
tions and Treg numbers. Whether there is a correlation between 
the disease severity and the degree of Treg dysfunction in LRBA-
deficient individuals needs to be analyzed in larger cohorts prior 
to initiation of immunosuppressive treatment. Furthermore, 
the lysosomal sorting function of LRBA might not be limited to 
T-lymphocytes and to CTLA-4, opening possibilities to evalu-
ate symtptoms of these patients, which are not fully explained 
by a  Treg-restricted dysfunction. To what extent additional 
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modifiers such as epigenetic or environmental factors might 
influence the disease outcome in LRBA- and CTLA-4-deficient 
patients, remains to be analyzed in further studies.
Since first description in 2012, about 50 LRBA-deficient patients 
have been detected and the number is increasing. Very recently 
Lévy et al. described two patients suffering from arthritis as their 
main clinical symptoms (18). We believe that the awareness of the 
heterogeneity of this disease among non-immunologists might 
be the key to the early detection and initiation of the treatment 
of LRBA deficiency. Without appropriate treatment, there is a 
high mortality in a majority of the affected patients. While some 
of the patients die early due to enteropathy and complications 
of the immunosuppressive treatment, others remain stable on 
systemic immunosuppression with glucocorticoids as single 
agents or as part of combinatorial therapy (6). Due to the lack of 
genotype–phenotype correlation in this disease and the clinical 
heterogeneity, the underlying diagnosis might remain undetected 
in some patients and lead to delayed treatment. These patients 
need early multidisciplinary care involving specialists in the fields 
of endocrinology, gastroenterology, and immunology. Supportive 
medical therapy of the evolving endocrine insufficiencies is indi-
cated at an early stage with continuous follow-up to detect further 
organ manifestations. Some patients may remain refractory to 
standard therapy. Extended immunosuppressive therapy may be 
necessary for patients with progressive symptoms of the disease 
and might result in stable disease but also can lead to lethal 
complications. Recently abatacept, a CTLA-4 fusion protein, 
was shown to provide improvement in LRBA-deficient patients 
(16). There is no long-term evaluation of efficacy and safety of 
the treatment available yet. In patients suffering from threatening 
autoimmunity, enteropathy and infectious complications of the 
immunosuppressive treatment early stem cell transplantation 
could be the only curative treatment option. A few LRBA-deficient 
patients being treated successfully by stem cell transplantation 
have been reported (6, 19). Further studies on transplantation 
in LRBA deficiency are necessary to evaluate the optimal con-
ditioning regimen and transplantation-related problems such as 
immune reconstitution posttransplantation and the risk of graft 
versus host disease. Given the severe fatal course of the disease 
in Patient 1, the establishment of a long-term treatment strategy 
including evaluation of a preemptive alloHSCT seems crucial for 
Patient 2 at this stage.
In light of a quite limited genotype–phenotype correlation, 
further data on LRBA-deficient patients are necessary to establish 
predictive prognostic biomarkers. Furthermore, detailed data 
on LRBA-deficient patients with an endocrine phenotype are 
necessary to evaluate the long-term risk of endocrine disorder, 
their outcome, and the optimal early treatment options in these 
patients.
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